Review of the TAXUS® Liberté™ SR paclitaxel-eluting coronary stent

Abstract

The advent of drug-eluting stents has revolutionized the treatment of coronary heart disease. Interventional cardiologists are increasingly treating more complex lesions in patients that would have otherwise required bypass surgery. As a result of technological advances, the second-generation thin strut TAXUS stent – the TAXUS^® Liberté™ SR paclitaxel-eluting coronary stent – has now been introduced into routine clinical practice. The Liberté stent has evolved from the currently available TAXUS Express™ stent to provide enhanced lesion access in challenging anatomies as well as more uniform drug delivery. This article will provide an overview of the TAXUS Liberté stent.

Keywords::

• drug-eluting stents
• paclitaxel
• Taxus^®
• restenosis
• Liberté™